Actuate Therapeutics (ACTU) Institutional Ownership $10.25 -0.73 (-6.68%) As of 03:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Actuate Therapeutics (NASDAQ:ACTU)Number ofInstitutional Buyers(last 12 months)12TotalInstitutional Inflows(last 12 months)$80.86MNumber ofInstitutional Sellers(last 12 months)0 Get ACTU Insider Trade Alerts Want to know when executives and insiders are buying or selling Actuate Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ACTU Institutional Buying and Selling by Quarter Actuate Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2025 Goldman Sachs Group Inc.22,358$151K0.0%+98.7%0.114% 5/14/2025 Voss Capital LP142,381$964K0.1%+157.7%0.729% 5/9/2025 Chicago Partners Investment Group LLC10,365$70K0.0%N/A0.053% 5/9/2025 Sfmg LLC11,000$74K0.0%N/A0.056% 5/2/2025 Sigma Planning Corp23,675$160K0.0%+47.3%0.121% 2/17/2025 OMERS ADMINISTRATION Corp10,583$84K0.0%N/A0.054% 2/14/2025 Mercer Global Advisors Inc. ADV16,344$130K0.0%N/A0.084% 2/14/2025 Voss Capital LP55,246$440K0.0%N/A0.283% 2/13/2025 Envestnet Asset Management Inc.10,465$83K0.0%N/A0.054% 2/10/2025 BIOS Capital Management LP9,893,651$78.75M83.7%N/A50.659% 2/6/2025 Freestone Capital Holdings LLC10,000$80K0.0%N/A0.051% 2/3/2025 Sigma Planning Corp16,075$128K0.0%N/A0.082% 11/12/2024 Northwestern University27,778$207K0.2%N/A0.142% 10/29/2024 KG&L Capital Management LLC12,000$89K0.0%N/A0.061% (Data available from 1/1/2016 forward) ACTU Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ACTU shares? During the previous two years, 12 institutional investors and hedge funds held shares of Actuate Therapeutics. The most heavily invested institutionals were BIOS Capital Management LP ($78.75M), Voss Capital LP ($964K), Northwestern University ($207K), Sigma Planning Corp ($160K), Goldman Sachs Group Inc. ($151K), Mercer Global Advisors Inc. ADV ($130K), and KG&L Capital Management LLC ($89K).Learn more on ACTU's institutional investors. Which institutional investors have been buying Actuate Therapeutics stock? Of the 12 institutional investors that purchased Actuate Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BIOS Capital Management LP ($9.89M), Voss Capital LP ($142.38K), Northwestern University ($27.78K), Sigma Planning Corp ($23.68K), Mercer Global Advisors Inc. ADV ($16.34K), KG&L Capital Management LLC ($12K), and Goldman Sachs Group Inc. ($11.11K). How much institutional buying is happening at Actuate Therapeutics? Institutional investors have bought a total of 10,179,347 shares in the last 24 months. This purchase volume represents approximately $80.86M in transactions. Related Companies CVAC Institutional Ownership CRMD Institutional Ownership CMRX Institutional Ownership CDMO Institutional Ownership CRON Institutional Ownership PRAX Institutional Ownership NRIX Institutional Ownership XERS Institutional Ownership BCAX Institutional Ownership OCS Institutional Ownership This page (NASDAQ:ACTU) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACTU Stock Free ACTU Stock Alerts